Deutsche Bank Starts Neurocrine Bio. (NBIX) at Buy

November 3, 2016 6:47 AM EDT
Get Alerts NBIX Hot Sheet
Price: $42.25 --0%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 6 | Down: 3 | New: 2
Trade NBIX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Deutsche Bank initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy rating and a price target of $65.

Analyst Andrew Peters said, "With two pre-commercial assets (including the wholly-owned Ingrezza in CNS disease), we view NBIX as one of the most encouraging fundamental stories in biotech. Indeed, we believe recent weakness driven by perceived commerical and competitive risks provide an entry point for investors ahead of a 1H17 product launch, a near-term clinical catalyst (Ingrezza in Tourette), and an underappreciated market opportunity in TD. Further, given the leverageability of a large-market CNS therapy, we would expect strategic interest to be very high although given recent FDA actions, we would expect interest to accelerate post-approval."

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $42.56 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

New Coverage

Related Entities

Deutsche Bank

Add Your Comment